Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcriptional repressor CTCFL, commonly known as Brother of the Regulator of Imprinted Sites (BORIS), is a cancer-testis antigen and a germline-specific paralog of the architectural chromatin protein CTCF. Under normal physiological conditions, BORIS is expressed exclusively during male germ cell development and spermatogenesis, where it plays a critical role in epigenetic reprogramming, gene imprinting, and chromatin remodeling. However, BORIS is aberrantly reactivated and overexpressed in a wide variety of human malignancies, including breast, ovarian, lung, and prostate cancers, particularly within cancer stem cell populations. In these cancer cells, BORIS competes with CTCF for DNA binding sites, disrupting the 3D genome architecture, altering the epigenetic landscape, and driving the expression of oncogenes and other cancer-testis antigens.
Because of its highly restricted expression in normal tissues and widespread activation in cancers, BORIS is considered an ideal target for cancer immunotherapy. Therapeutic strategies under development primarily focus on cancer vaccines, such as DNA vaccines, peptide-loaded dendritic cell therapies, and viral vector-based vaccines (e.g., VRP-mBORIS). To mitigate safety concerns regarding the oncogenic potential of functional BORIS and off-target autoimmune reactions due to the highly conserved zinc finger domain, these immunotherapies typically utilize a modified version of the protein that lacks the DNA-binding domain.
Active immunotherapy targeting cancer-testis antigen to induce cytotoxic T-lymphocyte responses against cancer stem cells
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcriptional repressor CTCFL (BORIS) (CTCFL).